Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Oct 16;10(10):CD005262.
doi: 10.1002/14651858.CD005262.pub4.

Pentoxifylline for intermittent claudication

Cathryn Broderick  1 , Rachel Forster  1 , Mohammed Abdel-Hadi  2 , Kareem Salhiyyah  3
Affiliations
Meta-Analysis

Pentoxifylline for intermittent claudication

Cathryn Broderick et al. Cochrane Database Syst Rev. .

Abstract

Background: Intermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is associated with high morbidity and mortality. Pentoxifylline, one of many drugs used to treat IC, acts by decreasing blood viscosity, improving erythrocyte flexibility, and promoting microcirculatory flow and tissue oxygen concentration. Many studies have evaluated the efficacy of pentoxifylline in treating people with PAD, but results of these studies are variable. This is the second update of a review first published in 2012.

Objectives: To determine the efficacy of pentoxifylline in improving the walking capacity (i.e. pain-free walking distance and total (absolute, maximum) walking distance) of people with stable intermittent claudication, Fontaine stage II.

Search methods: For this update, the Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases, and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 28 January 2020. There were no language restrictions.

Selection criteria: We included all double-blind, randomised controlled trials (RCTs) comparing pentoxifylline versus placebo or any other pharmacological intervention in people with IC Fontaine stage II.

Data collection and analysis: Two review authors independently selected studies for inclusion, assessed the included studies, matched data and resolved disagreements by discussion. Review authors assessed the methodological quality of studies using the Cochrane 'Risk of bias' tool and collected results related to the outcomes of interest, pain-free walking distance (PFWD), total walking distance (TWD), ankle-brachial pressure index (ABI), quality of life (QoL) and side effects. Comparison of studies was based on duration and dose of pentoxifylline. We used GRADE criteria to assess the certainty of the evidence.

Main results: We identified no new eligible studies for this update. This review includes 24 studies with 3377 participants. Seventeen studies compared pentoxifylline versus placebo. The seven remaining studies compared pentoxifylline with flunarizine (one study), aspirin (one study), Gingko biloba extract (one study), nylidrin hydrochloride (one study), prostaglandin E1 (two studies), and buflomedil and nifedipine (one study). Risk of bias for the individual studies was generally unclear because there was a lack of methodological reporting for many of the included studies, especially regarding randomisation and allocation methods. Most included studies did not provide adequate information to allow selective reporting to be judged and did not report blinding of assessors. Heterogeneity between included studies was considerable with regards to multiple variables, including duration of treatment, dose of pentoxifylline, baseline walking distance and participant characteristics; therefore, pooled analysis for comparisons which included more than one study, was not possible. Pentoxifylline compared to placebo Of 17 studies comparing pentoxifylline with placebo, 11 reported PFWD and 14 reported TWD; the difference in percentage improvement in PFWD for pentoxifylline over placebo ranged from -33.8% to 73.9% and in TWD ranged from 1.2% to 155.9%. It was not possible to pool the data of the studies because data were insufficient and findings from individual trials were unclear. Most included studies suggested a possible improvement in PFWD and TWD for pentoxifylline over placebo (both low-certainty evidence). The five studies which evaluated pre-exercise ABI comparing pentoxifylline and placebo found no evidence of a difference (moderate-certainty evidence). Two of the three studies that evaluated QoL between people who received pentoxifylline and placebo were larger studies that used validated QoL tools and generally found no evidence of a difference between groups. One small, short-term study, which did not specify which QoL tool was used, reported improved QoL in the pentoxifylline group (moderate-certainty evidence). Pentoxifylline generally was well tolerated; the most commonly reported side effects consisted of gastrointestinal symptoms such as nausea (low-certainty evidence). Certainty of the evidence from this review was low or moderate, with downgrading due to risk of bias concerns, inconsistencies between studies and the inability to evaluate imprecision because meta-analysis could not be undertaken. The seven remaining studies compared pentoxifylline with either flunarizine, aspirin, Gingko biloba extract, nylidrin hydrochloride, prostaglandin E1, or buflomedil and nifedipine; data were too limited to allow any meaningful conclusions to be made.

Authors' conclusions: There is a lack of high-certainty evidence for the effects of pentoxifylline compared to placebo, or other treatments, for IC. There is low-certainty evidence that pentoxifylline may improve PFWD and TWD compared to placebo, but no evidence of a benefit to ABI or QoL (moderate-certainty evidence). Pentoxifylline was reported to be generally well tolerated (low-certainty evidence). Given the large degree of heterogeneity between the studies, the role of pentoxifylline for people with IC Fontaine class II remains uncertain.

PubMed Disclaimer

Conflict of interest statement

CB: none.

RF: none.

MAH: none.

KS: none.

Figures

1
1
Study flow diagram.
2
2
Screen4Me flow diagram.
3
3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
4
4
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Accetto 1982 {published data only}
    1. Accetto B. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator-nylidrin. American Heart Journal 1982;103(5):864-9. - PubMed
Belcaro 2002 {published data only}
    1. Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Cesarone MR, Incandela L, et al. Intermittent claudication in diabetics: treatment with exercise and pentoxifylline – a 6-month, controlled, randomized trial. Angiology 2002;53 Suppl 1:39-43. - PubMed
Bohmer 1988 {published data only}
    1. Bohmer D, Kalinski S, Michaelis P, Szogy A. Efficacy and tolerance of Ginkgo biloba extract compared to that of pentoxifylline in the treatment of patients suffering from peripheral chronic arterial occlusive disease. Hers Kreislauf 1988;20(1):5-8.
Bollinger 1977 {published data only}
    1. Bollinger A, Frei CH. Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1977;1(9):557-62.
Cesarone 2002 {published data only}
    1. Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Incandela L, et al. Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial. Angiology 2002;53 Suppl 1:1-5. - PubMed
Chacon‐Quevedo 1994 {published data only}
    1. Chacon-Quevedo A, Eguaras MG, Calleja F, Garcia MA, Roman M, Casares J, et al. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs. Angiology 1994;45(7):647-53. - PubMed
Ciocon 1997 {published data only}
    1. Ciocon JO, Galindo-Ciocon D, Galindo DJ. A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly. Angiology 1997;48(3):237-40. - PubMed
Creager 2008 {published data only}
    1. Creager MA, Pande RL, Hiatt WR. A randomized trial of iloprost in patients with intermittent claudication. Vascular Medicine 2008;13(1):5-13. - PubMed
Dawson 2000 {published data only}
    1. Dawson DL, Beebe HG, Herd JA, Chinoy DA, Davidson MH, Hiatt WR, et al. Cilostozol or pentoxifylline for claudication. Circulation 1998;98 Suppl 1:1-12.
    1. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine 2000;109(7):523-30. - PubMed
    1. Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DV Jr. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology 2002;53(5):509-20. - PubMed
De Sanctis 2002a {published data only}
    1. De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Incandela L, et al. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial – walking distance and microcirculation. Angiology 2002;53 Suppl 1:7-12. - PubMed
De Sanctis 2002b {published data only}
    1. De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Incandela L, et al. Treatment of long-distance intermittent claudication with pentoxifylline: a 12-month, randomized trial. Angiology 2002;53 Suppl 1:13-7. - PubMed
Di Perri 1983 {published data only}
    1. Di Perri T, Guerrini M. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology 1983;34(1):40-5. - PubMed
Donaldson 1984 {published data only}
    1. Donaldson DR, Hall TJ, Kester RC, Ramsden CW, Wiggins PA. Does oxpentifylline ('Trental') have a place in the treatment of intermittent claudication? Current Medical Research and Opinion 1984;9(1):35-40. - PubMed
    1. Donaldson DR, Kester RC, Russell CW, Wiggins PA, Hall TJ. Does oxpentifylline (Trental) have a place in the treatment of intermittent claudication? Clinical Hemorheology 1981;1(5-6):469. - PubMed
Ernst 1992 {published data only}
    1. Ernst E, Kollar L, Resch KL. Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial. Angiology 1992;43(2):121-5. - PubMed
Gallus 1985 {published data only}
    1. Gallus AS, Gleadow F, Dupont P, Walsh J, Morley AA, Wenzel A, et al. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Australian and New Zealand Journal of Medicine 1985;15(4):402-9. - PubMed
Hepp 1992 {published data only}
    1. Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Clinical comparison of the effect of I.U. prostaglandin E1 and I.U. pentoxifylline in patients with arterial occlusive disease [Vergleich der klinischen wirksamkeit von i.v. prostaglandin E1 und i.v. pentoxifyllin bei patienten mit arterieller verschlubkrankheit im stadium llb nach fontaine]. VASA 1992;21(4):447 Abstract No. 6.3. - PubMed
    1. Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Intravenous prostaglandin E1 versus pentoxifylline: a randomized controlled study in patients with intermittent claudication. International Angiology 1995;14 Suppl 1:280.
    1. Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Therapeutic effectiveness of PGE1 intravenous administered comparising with pentoxifylline on intermittent claudication [Therapeutische wirksamheit von intravenos verabreichtem PGE1 in vergleich mit pentoxifyllin bei claudicatio intermittens]. ANGIO 1992;14(2):59-64.
    1. Hepp W, Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Randomized study comparing the clinical effectiveness of intravenous prostaglandin E1 and intravenous pentoxifylline in patients with Fontaine stage IIb arterial occlusive disease [Randomisierte studie zum vergleich der klinischen wirksamkeit von i.v. prostaglandin E1 and i.v. pentoxifyllin bei patienten mit arterieller verschlubkrankheit im stadium IIb nach fontaine]. VASA. Supplementum 1991;33:348-9. - PubMed
Kiesewetter 1988 {published data only}
    1. Kiesewetter H, Blume J, Jung F, Waldhausen P, Gerhards M. Intermittent claudication. Increase in walking distance and improvement of hemorheologic parameters by pentoxifylline (Trental 400). MMW, Munchener Medizinische Wochenschrift 1988;130:357-60.
Lee 2001a {published data only}
    1. Lee TM, Su SF, Hwang JJ, Tseng CD, Chen MF, Lee YT, et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis 2001;158(2):471-6. - PubMed
    1. Lee TM, Su SF, Tsai CH, Lee YT, Wang SS. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science 2001;101(3):305-11. - PubMed
Lindgarde 1989 {published data only}
    1. Lindgarde F, Jelnes R, Bjorkman H, Adielsson G, Kjellstrom T, Palmquist I, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989;80(6):1549-56. - PubMed
Perhoniemi 1984 {published data only}
    1. Perhoniemi V, Salmenkivi K, Sundberg S, Johnsson R, Gordin A. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication. Angiology 1984;35(6):366-72. - PubMed
Porter 1982a {published data only}
    1. Gillings D, Koch G, Reich T, Stager WJ. Another look at the pentoxifylline efficacy data for intermittent claudication. Journal of Clinical Pharmacology 1987;27(8):601-9. - PubMed
    1. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. American Heart Journal 1982;104(1):66-72. - PubMed
    1. Reich T, Cutler BC, Lee BY, Porter JM, Reichle FA, Scogin JT, et al. Pentoxifylline in the treatment of intermittent claudication of the lower limbs. Angiology 1984;35(7):389-95. - PubMed
    1. Reich T, Gillings D. Effects of pentoxifylline on severe intermittent claudication. Angiology 1987;38(9):651-6. - PubMed
Porter 1982b {published data only}
    1. Porter JM, Bauer GM. Pharmacologic treatment of intermittent claudication. Surgery 1982;92(6):966-71. - PubMed
Schellong 2012 {published data only}
    1. NCT01263925. Prostaglandin E1 in outpatients with intermittent claudication. clinicaltrials.gov/ct2/show/NCT01263925 (first received 21 December 2010).
    1. Schellong S, Baron Von Bilderling P, Grus JD, Lawall H, Grieger F, Ney U, et al. Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication: results of a clinical study. VASA 2012;41(Suppl 82):78. - PubMed
    1. Schellong SM, Bilderling P, Gruss JD, Lawall H, Grieger F, Ney U, et al. Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication: results of a randomised clinical trial. VASA 2017;46(5):403-5. - PubMed
Volker 1978 {published data only}
    1. Volker D. Treatment of arterial diseases with Trental 400. Results of a double-blind study. Die Medizinische Welt 1978;29(32):1244-7. - PubMed

References to studies excluded from this review

Bieron 2005 {published data only}
    1. Bieron K, Kostka-Trabka E, Starzyk D, Goszcz A, Grodzinska L, Korbut R. Bencyclane – a new aspect of the mechanism of action in patients with peripheral arterial occlusive disease. Open-label, prospective, randomized trial. Acta Angiologica 2005;11(3):157-72.
Ciuffetti 1991 {published data only}
    1. Ciuffetti G, Mercuri M, Ott C, Lombardini R, Paltriccia R, Lupattelli G, et al. Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study. European Journal of Clinical Pharmacology 1991;41(6):511-5. - PubMed
Dawson 1999 {published data only}
    1. Dawson DL, DeMaioribus CA, Hagino RT, Light JT, Bradley DV Jr, Britt KE, et al. The effect of withdrawal of drugs treating intermittent claudication. American Journal of Surgery 1999;178(2):141-6. - PubMed
Dettori 1989 {published data only}
    1. Dettori AG, Pini M, Moratti A, Paolicelli M, Basevi P, Quintavalla R, et al. Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group. Angiology 1989;40(4 part 1):237-48. - PubMed
Ehrly 1986 {published data only}
    1. Ehrly AM, Saeger-Lorenz K. Effect of pentoxifylline on the muscle tissue oxygen pressure of claudicants after pedoergometric exercise. Angiology 1986;37(5):398.
Ehrly 1987 {published data only}
    1. Ehrly AM, Saeger-Lorenz K. Influence of pentoxifylline on muscle tissue oxygen tension (pO2) of patients with intermittent claudication before and after pedal ergometer exercise. Angiology 1987;38(2 part 1):93-100. - PubMed
Farkas 1993 {published data only}
    1. Farkas K, Horvath P, Farsang C. Pentoxifylline treatment of patients with peripheral obstructive vascular disease. International Angiology 1993;12:64.
Fossat 1995 {published data only}
    1. Fossat C, Fabre D, Alimi Y, Bienvenu J, Aillaud MF, Lenoble M, et al. Leukocyte activation study during occlusive arterial disease of the lower limb: effect of pentoxifylline infusion. Journal of Cardiovascular Pharmacology 1995;25 Suppl 2:96-100. - PubMed
Geppert 2017 {published data only}
    1. Geppert T, Kirchhof C, Schmidt-Lucke C, Schmidt-Lucke A. Superior therapeutic effect of intermittent vasodilator infusion therapy on walking distance among patients with peripheral arterial disease and intermittent claudication. VASA 2017;46(Suppl 97):29.
Guest 2005 {published data only}
    1. Guest JF, Davie AM, Clegg JP. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. Current Medical Research and Opinion 2005;21(6):817-26. - PubMed
Hepp 1996 {published data only}
    1. Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Clinical efficacy of IV prostaglandin E1 and IV pentoxifylline in patients with arterial occlusive disease of fontaine stage IIb: a multicenter, randomized comparative study. International Journal of Angiology 1996;5(1):32-7.
Horowitz 1982 {published data only}
    1. Horowitz I. Results of a multicenter randomised double blind study. Pentoxyifylline versus placebo for 6 months on lower limb artertiopathies [Resultats d'une etude multicentrique randomisee en double aveugle. Pentoxifylline contre placebo prolongee sur 6 mois dans les arteriopathies des membres inferieurs]. Actualities D'Angiologie 1982;7:31-4.
Incandela 2002 {published data only}
    1. Incandela L, De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Geroulakos G, et al. Short-range intermittent claudication and rest pain: microcirculatory effects of pentoxifylline in a randomized, controlled trial. Angiology 2002;53 Suppl 1:27-30. - PubMed
Kellner 1976 {published data only}
    1. Kellner H. Treatment of chronic arterial circulatory disorders. Double blind trial with Trental 400. MMW, Munchener Medizinische Wochenschrift 1976;118(43):1399-402. - PubMed
Luk'Janov 1995 {published data only}
    1. Luk'Janov Y. Hemorheologic and hemodynamic changes after treatments with PGE versus pentoxifylline (PF) in patients with peripheral arterial disease (PAD). International Angiology 1995;14 Suppl 1:372.
Milio 2003 {published data only}
    1. Milio G, Cospite V, Cospite M. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease. Minerva Cardioangiologica 2003;51(3):311-6. - PubMed
Milio 2006 {published data only}
    1. Milio G, Coppola G, Novo S. The effects of prostaglandin E-1 in patients with intermittent claudication. Cardiovascular & Hematological Disorders Drug Targets 2006;6(2):71-6. - PubMed
Panchenko 1997 {published data only}
    1. Panchenko E, Eshkeeva A, Dobrovolsky A, Titaeva E, Podinovskaya Y, Hussain KM, et al. Effects of indobufen and pentoxifylline on walking capacity and hemostasis in patients with intermittent claudication: results of six months treatment. Angiology 1997;48(3):247-54. - PubMed
Pignoli 1985 {published data only}
    1. Pignoli P, Ciccolo F, Villa V, Longo T. Comparative evaluation of buflomedil and pentoxifylline in patients with peripheral arterial occlusive disease. Current Therapeutic Research 1985;37(4):596-606.
Poggesi 1985 {published data only}
    1. Poggesi L, Scarti L, Boddi M, Masotti G, Serneri GG. Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis. Angiology 1985;36(9):628-37. - PubMed
Regenthal 1991 {published data only}
    1. Regenthal R, Voigt H, Reuter W, Preiss R. The effect of oral trapidil therapy on clinical and hemorheological parameters in arteriosclerosis obliterans in comparison to pentoxifylline – a pilot study. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1991;46(6):185-90. - PubMed
Reilly 1987 {published data only}
    1. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. New Zealand Medical Journal 1987;100(828):445-7. - PubMed
Rodin 1998a {published data only}
    1. Rodin SM. Pletal (cilostazol) tablets. Center for Drug Evaluation and Research. Application number: NDA 20-863, 1998;Study 21-96-202:27-40.
Rodin 1998b {published data only}
    1. Rodin SM. Pletal (cilostazol) tablets. Center for Drug Evaluation and Research. Application number: NDA 20-863 Otsuka America, 1998;Study 21-94-301:58-72.
Roekaerts 1984 {published data only}
    1. Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 1984;35(7):396-406. - PubMed
Rudofsky 1987 {published data only}
    1. Rudofsky G, Haussler KF, Kunkel HP, Schneider-May H, Spengel F, Symann O, et al. Effectiveness of intravenous infusion treatment of peripheral arterial occlusive disease with Trental – results of a multicenter double-blind study [Zur wirksamkeit einer intravenosen infusionbehandlung der peripheren arteriellen verschlubkrankheit mit Trental – Ergebnisse einer multi-zentrischen doppelblindstudie]. VASA. Supplementum 1987;20:375-8. - PubMed
Rudofsky 1988 {published data only}
    1. Rudofsky G, Haussler KF, Kunkel HP, Schneider-May H, Spengel F, Symann O, et al. Intravenous pentoxifylline treatment in chronic peripheral arterial disease. Die Medizinische Welt 1988;39(39):1136-40.
Rudofsky 1989 {published data only}
    1. Rudofsky G, Haussler KF, Kunkel HP, Schneider-May H, Spengel F, Symann O, et al. Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline. Angiology 1989;40(7):639-49. - PubMed
Scheffler 1991 {published data only}
    1. Scheffler P, la Hamette D, Muller H. Controlled vascular training in IIb peripheral arterial occlusive disease: additive effect of intravenous PGE1 versus intravenous pentoxifylline during training. VASA. Supplementum 1991;33:350-2. - PubMed
Scheffler 1994 {published data only}
    1. Scheffler P, la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 1994;90(2):818-22. - PubMed
Schubotz 1976 {published data only}
    1. Schubotz R. Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders. Pharmatherapeutica 1976;1(3):172-9.
Shustov 1997 {published data only}
    1. Shustov SB, Canova N. Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease. Current Medical Research and Opinion 1997;13(10):573-82. - PubMed
Singh 2009 {published data only}
    1. Singh S, Singh H, Kohli A, Kapoor V, Singh G. Effects of cilostazole and pentoxifylline on claudication distance and lipid profile in patients with occlusive peripheral arterial disease: a comparative trial. Indian Journal of Thoracic Cardiovascular Surgery 2009;25:45-8.
Skovborg 1983 {published data only}
    1. Skovborg F, Bonde-Petersen F, Bloch I, Christensen E. Intermittent claudication treated with pentoxyphylline. A controlled trial [Claudicatio intermittens behandlet med pentoksyfyllin]. Ugeskrift for laeger 1983;145(47):3649-52. - PubMed
Strano 1984 {published data only}
    1. Strano A, Davi G, Avellone G, Novo S, Pinto A. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 1984;35(7):459-66. - PubMed
Strano 2002 {published data only}
    1. Strano A. Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication. Clinical Drug Investigation 2002;22 Suppl 1:1-6. - PubMed
Thomson 1990 {published data only}
    1. Thomson GJ, Thomson S, Todd AS, Vohra RK, Carr MH, Walker MG. Combined intravenous and oral pentoxifylline in the treatment of peripheral vascular disease. A clinical trial. International Angiology 1990;9(4):266-70. - PubMed
Tonak 1977 {published data only}
    1. Tonak J, Knecht H, Groitl H. Treatment of circulation disorders with pentoxifylline. A double-blind study with Trental [Zur behandlung von durchblutungsstorungen mit pentoxifyllin. Eine doppelblindstudie mit trental]. Medizinische Monatsschrift 1977;31(10):467-72. - PubMed
Triebe 1992 {published data only}
    1. Triebe G, Munnich U, Liebold F. A therapeutic comparison between hemodilution and pentoxifylline in arterial obstructive disease. An objective assessment by quantitative Doppler sonography. Deutsche Medizinische Wochenschrift 1992;117(14):523-30. - PubMed
Tsang 1994 {published data only}
    1. Tsang GM, Sanghera K, Gosling P, Smith FC, Paterson IS, Simms MH, et al. Pharmacological reduction of the systemically damaging effects of local ischaemia. European Journal of Vascular Surgery 1994;8(2):205-8. - PubMed
Wang 2003 {published data only}
    1. Wang T, Elam MB, Forbes WP, Zhong J, Nakajima K. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis 2003;171(2):337-42. - PubMed

Additional references

Bachoo 2010
    1. Bachoo P, Thorpe PA, Maxwell H, Welch K. Endovascular stents for intermittent claudication. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003228. [DOI: 10.1002/14651858.CD003228.pub2] - DOI - PMC - PubMed
Bedenis 2014
    1. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No: CD003748. [DOI: 10.1002/14651858.CD003748.pub4] - DOI - PMC - PubMed
Dawson 2002
    1. Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DV Jr. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology 2002;53(5):509-20. - PubMed
de Backer 2012
    1. Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No: CD001368. [DOI: 10.1002/14651858.CD001368.pub4] - DOI - PubMed
de Backer 2013
    1. Backer TL, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No: CD000988. [DOI: 10.1002/14651858.CD000988.pub4] - DOI - PMC - PubMed
Ernst 1994
    1. Ernst E. Pentoxifylline for intermittent claudication. A critical review. Angiology 1994;45(5):339-45. - PubMed
ESC 2018
    1. Aboyans V, Ricco JB, Bartelink ML, Björck M, Brodmann M, Cohnert T, ESC Scientific Document Group, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. European Heart Journal 2018;39(9):763-816. [DOI: 10.1093/eurheartj/ehx095] - DOI - PubMed
ESVM 2019
    1. PAD Guideline Writing Group. European Society for Vascular Medicine (ESVM) – guideline on peripheral arterial disease. VASA 2019;48(Suppl 102):1-79. [DOI: 10.1024/0301-1526/a000834] - DOI - PubMed
Fontaine 1954
    1. Fontaine VR, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders [Die chirurgische Behandlung der peripheren Durchblutungsstörungen]. Helvetica Chirurgica Acta 1954;21(5-6):499-533. - PubMed
Fowkes 1998
    1. Fowkes G, Gillespie IN. Angioplasty (versus non surgical management) for intermittent claudication. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No: CD000017. [DOI: 10.1002/14651858.CD000017] - DOI - PubMed
Fowkes 2013
    1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382(9901):1329-40. - PubMed
Frampton 1995
    1. Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs & Aging 1995;7(6):480-503. - PubMed
Gillings 1987
    1. Gillings D, Koch G, Reich T, Stager WJ. Another look at the pentoxifylline efficacy data for intermittent claudication. Journal of Clinical Pharmacology 1987;27(8):601-9. - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Lane 2017
    1. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No: CD000990. [DOI: 10.1002/14651858.CD000990.pub4] - DOI - PMC - PubMed
Langendam 2013
    1. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane reviews. Systematic Reviews 2013;2:81. [DOI: 10.1186/2046-4053-2-81] - DOI - PMC - PubMed
Lee 2001b
    1. Lee TM, Su SF, Hwang JJ, Tseng CD, Chen MF, Lee YT, et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis 2001;158(2):471-6. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Marshall 2018
    1. Marshall IJ, Noel-Storr AH, Kuiper J, Thomas J, Wallace BC. Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide. Research Synthesis Methods 2018;9(4):602-14. - PMC - PubMed
McDonald 2017
    1. McDonald S, Noel-Storr AH, Thomas J. Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. Global Evidence Summit; 2017 Sept 13-16; Cape Town, South Africa.
Medline Plus
    1. Medline Plus. Pentoxifylline. https://medlineplus.gov/druginfo/meds/a685027.html (accessed 17 September 2020).
Meijer 2002
    1. Meijer WT, Cost B, Bernsen RM, Hoes AW. Incidence and management of intermittent claudication in primary care in The Netherlands. Scandinavian Journal of Primary Health Care 2002;20(1):33-4. - PubMed
Meng 2014
    1. Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology 2014;65(3):190-7. - PubMed
MICROMEDEX 2002
    1. MICROMEDEX, Englewood, Colorado (Edition expires [12/2002]). MICROMEDEX® Healthcare Series. lrs.lendac.ie/m&p.html (accessed for original version 2011, no longer available).
Moher 2000
    1. Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 2000;59(5):1057-70. - PubMed
NICE 2011
    1. National Institute for Health and Care Excellence (NICE). Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. www.nice.org.uk/ guidance/TA223/chapter/2-Clinical-need-and-practice (accessed 5 April 2015).
NICE 2012
    1. National Institute for Health and Care Excellence (NICE). Lower limb peripheral arterial disease: diagnosis and management. www.nice.org.uk/Guidance/CG147 (accessed 5 April 2015).
Noel‐Storr 2018
    1. Noel-Storr AH, the Project Transform team. Cochrane Crowd: new ways of working together to produce health evidence. Evidence Live 2018; 2018 Jun 18-20; Oxford (UK).
Reich 1984
    1. Reich T, Cutler BC, Lee BY, Porter JM, Reichle FA, Scogin JT, et al. Pentoxifylline in the treatment of intermittent claudication of the lower limbs. Angiology 1984;35(7):389-95. - PubMed
Robertson 2013
    1. Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No: CD000986. [DOI: 10.1002/14651858.CD000986.pub3] - DOI - PMC - PubMed
Sanofi
    1. Sanofi. Pentoxifylline. medicines.org.uk/emc/medicine/338/SPC/Trental+400/#PHARMACEUTICAL_PARTS (accessed 17 September 2020).
Schellong 2017
    1. Schellong SM, Bilderling P, Gruss JD, Lawall H, Grieger F, Ney U, et al. Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication: results of a randomised clinical trial. VASA 2017;46(5):403-5. - PubMed
Squires 2010
    1. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for intermittent claudication in people with peripheral arterial disease. Technology Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Clinical Excellence 2010.
Squires 2011
    1. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technology Assessment 2011;15(40):1-210. - PMC - PubMed
Stevens 2012
    1. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery 2012;99(12):1630-8. - PubMed
Tendera 2011
    1. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clement D, Collet J-P, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. European Heart Journal 2011;32:2851-906. - PubMed
Thomas 2017
    1. Thomas J, Noel-Storr AH, Marshall I, Wallace B, McDonald S, Mavergames C, et al. Living systematic review network. Living systematic reviews: 2. Combining human and machine effort. Journal of Clinical Epidemiology 2017;91:31-7. - PubMed
Wong 2011
    1. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No: CD001272. [DOI: 10.1002/14651858.CD001272] - DOI - PMC - PubMed

References to other published versions of this review

Salhiyyah 2005
    1. Salhiyyah K, Palfreyman SS, Booth A, Michaels JA, Senanayake E. Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No: CD005262. [DOI: 10.1002/14651858.CD005262] - DOI - PubMed
Salhiyyah 2012
    1. Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No: CD005262. [DOI: 10.1002/14651858.CD005262.pub2] - DOI - PubMed
Salhiyyah 2015
    1. Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No: CD005262. [DOI: 10.1002/14651858.CD005262.pub3] - DOI - PMC - PubMed

Publication types

MeSH terms